Judgment Termination of the Proceeding | Nov 8, 2018 | PAPER | BOARD |
Email | Nov 8, 2018 | EXHIBIT | BOARD |
Joint Motion to Terminate Proceeding | Oct 31, 2018 | PAPER | PETITIONER |
EX2013 - Horning | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2015 - Czuczman 1999 | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2016 - Gribben | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2017 - Rigacci | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2021 - Han | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2024 - Korsmeyer | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2025 - Leget | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2027 - Kimby | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2028 - Czuczman 1996 | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2029 - Hoppe | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2011 - Al-Ismail | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2014 - Lopez-Guillermo | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2018 - Czuczman 2004 | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2019 - Dep. Tr. of Robert J. Soiffer, M.D. | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2020 - Ezdinli | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2023 - Rituxan Prescribing Information | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2030 - Raphael | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2032 - Fisher | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2033 - Rosenberg | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2036 - McLaughlin 1992 | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2043 - Young | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2031 - McNeil | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2034 - Peterson | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2035 - McLaughlin 1987 | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2037 - Smalley | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2038 - Maccio | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2039 - Weijl | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2040 - McLaughlin 1998 | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2042 - Solal-Celigny | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2101 - Dep. Tr. of Robert J. Soiffer, M.D. (IPR2017-01168) | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
EX2022 - Declaration of Sayem Osman | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
Patent Owner's Response | Oct 8, 2018 | PAPER | PATENT OWNER |
EX2012 - Declaration of Peter McLaughlin, M.D. | Oct 8, 2018 | EXHIBIT | PATENT OWNER |
Notice of Deposition of Robert J. Soiffer | Aug 27, 2018 | PAPER | PATENT OWNER |
Patent Owner's Objections to Evidence | Aug 21, 2018 | PAPER | PATENT OWNER |
Order Granting Petitioner's Motion for Pro Hac Vice Recognition of
Mr. Amit H. Thakore and Mr. Leon Miniovich | Aug 14, 2018 | PAPER | BOARD |
Ex. 1039 - Declaration of Robert Soiffer, M.D. | Aug 14, 2018 | EXHIBIT | PETITIONER |
Petitioner's Updated Exhibit List (As Of August 14, 2018) | Aug 14, 2018 | PAPER | PETITIONER |
Joint Stipulation to Modify Due Dates 1-5 | Aug 13, 2018 | PAPER | PATENT OWNER |
Decision - 37 C.F.R. 42.5 | Aug 10, 2018 | PAPER | BOARD |
Petitioner's Unopposed Motion For PHV Admission Of Amit H. Thakore And Leon Miniovich | Aug 1, 2018 | PAPER | PETITIONER |
Ex. 1037 Declaration Of Amit H. Thakore ISO Unopposed Motion for PHV Admission | Aug 1, 2018 | EXHIBIT | PETITIONER |
Ex. 1038 Declaration Of Leon Miniovich ISO Unopposed Motion for PHV Admission | Aug 1, 2018 | EXHIBIT | PETITIONER |
Petitioner's Updated Exhibit List (As Of August 1, 2018) | Aug 1, 2018 | PAPER | PETITIONER |
Petitioner's Updated Power Of Attorney Appointing Additional Counsel | Aug 1, 2018 | PAPER | PETITIONER |
Petitioner's Updated Mandatory Notice | Aug 1, 2018 | PAPER | PETITIONER |
Petitioner's Unopposed Motion To Substitute The Declaration Of Dr. Ozer | Jul 20, 2018 | PAPER | PETITIONER |
Petitioner's Service of Supplemental Evidence | Jul 13, 2018 | PAPER | PETITIONER |
Petitioner's Updated Exhibits List (as of July 13, 2018 | Jul 13, 2018 | PAPER | PETITIONER |
Patent Owner's Objections to Evidence Under 37 C.F.R. 42.64 | Jun 28, 2018 | PAPER | PATENT OWNER |
Petitioner¿¿¿s Objections To Exhibits | Jun 28, 2018 | PAPER | PETITIONER |
Scheduling Order | Jun 18, 2018 | PAPER | BOARD |
Decision Institution of Inter Partes Review | Jun 14, 2018 | PAPER | BOARD |
Patent Owners Sur-Reply to Petitioners Reply | Apr 18, 2018 | PAPER | PATENT OWNER |
Patent Owners Mandatory Notice Updating Related Matters | Apr 18, 2018 | PAPER | PATENT OWNER |
Petitioner¿¿¿s Authorized Reply To Patent Owner Preliminary Response | Apr 11, 2018 | PAPER | PETITIONER |
DECISION Granting Motion for Pro Hac Vice Recognition of Mr. Charles B. Klein and Mr. Eimeric Reig-Plessis | Apr 4, 2018 | PAPER | BOARD |
DECISION Conduct of the Proceeding | Apr 4, 2018 | PAPER | BOARD |
EX2001 - File History of U.S. Patent Application No. 09/372,202 | Mar 19, 2018 | EXHIBIT | PATENT OWNER |
EX2004 - File History for Application No. 11/840,956 | Mar 19, 2018 | EXHIBIT | PATENT OWNER |
EX2005 - File History for Application No. 13/521,896 | Mar 19, 2018 | EXHIBIT | PATENT OWNER |
EX2002 - Carlson | Mar 19, 2018 | EXHIBIT | PATENT OWNER |
EX2003 - Czuczman | Mar 19, 2018 | EXHIBIT | PATENT OWNER |
EX2006 - Declaration of Megan Raymond | Mar 19, 2018 | EXHIBIT | PATENT OWNER |
EX2007 - Deposition Transcript of Izidore Lossos, M.D. | Mar 19, 2018 | EXHIBIT | PATENT OWNER |
EX2008 - Hagenbeek | Mar 19, 2018 | EXHIBIT | PATENT OWNER |
EX2009 - Demidem | Mar 19, 2018 | EXHIBIT | PATENT OWNER |
EX2010 - Maloney | Mar 19, 2018 | EXHIBIT | PATENT OWNER |
Patent Owner Preliminary Response | Mar 19, 2018 | PAPER | PATENT OWNER |
Petitioner's Unopposed Motion For PHV Admission Of Charles B. Klein and Eimeric Reig-Plessis | Feb 2, 2018 | PAPER | PETITIONER |
Ex. 1034 - Declaration Of Charles B. Klein ISO PHV Motion | Feb 2, 2018 | EXHIBIT | PETITIONER |
Ex. 1035 - Declaration Of Eimeric Reig-Plessis ISO PHV Motion | Feb 2, 2018 | EXHIBIT | PETITIONER |
PETITIONER'S UPDATED EXHIBIT LIST (AS OF FEBRUARY 2, 2018) | Feb 2, 2018 | PAPER | PETITIONER |
Petitioner's Updated Mandatory Notice | Jan 31, 2018 | PAPER | PETITIONER |
Power of Attorney | Dec 22, 2017 | PAPER | PATENT OWNER |
Mandatory Notice | Dec 22, 2017 | PAPER | PATENT OWNER |
Notice of Accord Filing Date | Dec 18, 2017 | PAPER | BOARD |
Ex. 1001 - Antonio J. Grillo-Lopez, U.S. Patent No. 9,296,821 B2 | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1008 - Marcus et al., "CVP Chemotherapy Plus Rituximab Compared with CVP as First-Line Treatment for Advanced Follicular Lymphoma," Blood, 105(4):1417-1423 (2005) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1011 - Rituxan (rituximab) labeling (Nov. 1997) ("FDA label") | Dec 1, 2017 | EXHIBIT | PETITIONER |
Petitioner 's Power of Attorney | Dec 1, 2017 | PAPER | PETITIONER |
Ex. 1003 - Steward et al., "Maintenance Chlorambucil After CVP in the Management of Advanced Stage, Low-Grade Histologic Type Non-Hodgkin's Lymphoma," Cancer, 61(3):441-447 (1998) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1004 - Czuczman et al., "IDEC-C2B8 and CHOP Chemoimmunotherapy of Low-Grade Lymphoma," Blood, 86(10 Supp. 1):55a (1995) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1005 - Maloney et al., "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma," Blood, 90(6):2188-2195 (1997) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1006 - Kenneth A. Foon & Richard I. Fisher, "Lymphomas" in Williams Hematology 5th Ed. (Ernest Beutler et al., eds.) 1076-1096 (1995) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1007 - Dana et al., "Long-Term Follow-Up of Patients with Low-Grade Malignant Lymphomas Treated with Doxorubicin-Based Chemotherapy or Chemoimmunotherapy," J. Clinical Oncology 11(4):644-651 (1993) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1009 - Lauren C. Pinter-Brown and Dennis A. Casciato, "Hodgkin and Non-Hodgkin Lymphoma," in Manual of Clinical Oncology 6th Ed. (Dennis A. Casciato, ed.) 431-470 (2009) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1010 - Anderson et al., U.S. Patent No. 5,736,137 | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1012 - Physicians' Desk Reference (53rd ed. 1999) (excerpted), "Rituxan (Rituximab)" ("PDR label") | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1013 - Maloney et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma," J. Clinical Oncology, 15(10):3266-3274 (1997) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1021 - Declaration of Sylvia D. Hall-Ellis, Ph.D. | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1024 - U.S. Application No. 09/372,202 (dated August 11, 1999) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1027 - U.S. Application No. 13/524,896, Amendment and Response (dated April 25, 2014) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1028 - U.S. Application No. 13/524,896, Final Office Rejection (dated September 16, 2014) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1014 - Arthur T. Skarin & David M. Dorfman, "Non-Hodgkin's Lymphomas: Current Classification and Management," CA Cancer J. Clinicians, 47(6):351-372 (1997) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1015 - W. Hiddemann, "Non-Hodgkin's Lymphoma-Current Status of Therapy and Future Perspectives," Eur. J. Cancer, 31A:2141-2145 (1995) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1016 - Sriskandan et al., "Aggressive Management of Doxorubicin-Induced Cardiomyopathy Associated with 'Low' Doses of Doxorubicin," Postgraduate Med. J., 70(828):759-761 (1994) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1017 - Bishop et al., "A Randomized Trial of High Dose Cyclophosphamide, Vincristine, and Prednisone Plus or Minus Doxorubicin (CVP Versus CAVP) with Long-Term Follow-up in Advanced Non-Hodgkin's Lymphoma," Leukemia, 1(6):508-513 (1987) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1018 - McLaughlin et al., "Rituximab Chimeric Anti-CD Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program," J. Clinical Oncology, 16(8):2825-2833 (1998) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1019 - Pierre Feugier, "A Review of Rituximab, the First Anti-CD20 Monoclonal Antibody Used in the Treatment of B Non-Hodgkin's Lymphomas," Future Oncology, 11(9):1327-1342 (2015) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1020 - Demidem et al., "Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs," Cancer Biotherapy & Radiopharmaceuticals, 12(3):177-186 (1997) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1022 - Institution of Inter Partes Review, Celltrion, Inc. v. Biogen, Inc., IPR2017-01095 (U.S. Patent No. 9,296,821) Paper 12 (PTAB) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1023 - Petition for Inter Partes Review, Celltrion, Inc. v. Biogen, Inc., IPR2017-01095 (U.S. Patent No. 9,296,821) Paper 2 (PTAB) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1025 - U.S. Application No. 13/524,896, Non-Final Office Action (dated December 31, 2012) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1026 - U.S. Application No. 13/524,896, Amendment and Response (dated March 28, 2013) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1029 - U.S. Application No. 13/524,896, Amendment and Response (dated September 18, 2015) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1030 - U.S. Application No. 13/524,896, Applicant-Initiated Interview Summary and Notice of Issuance (dated February 26, 2016) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1031 - U.S. Provisional Application No. 60/096,180 (filed August 11, 1998) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1032 - Michael J. Campbell & John E. Niederhuber, "B-Lymphocyte Responses," Clinical Oncology, Abeloff et al., Eds. (1995), 100-126 | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1033 - Michael L. Grossbard and Pratik S. Multani, "Clinical Status and Optimal Use of Rituximab for B-Cell Lymphomas," Psychiatric Times, (December 1, 1998) | Dec 1, 2017 | EXHIBIT | PETITIONER |
Ex. 1002 - Declaration of Howard Ozer, M.D., Ph.D. | Dec 1, 2017 | EXHIBIT | PETITIONER |
PETITION FOR INTER PARTES REVIEW (NHL '821) | Dec 1, 2017 | PAPER | PETITIONER |